Home > Healthcare > Pharmaceuticals > Finished Drug Form > loratadine market
Get a free sample of Loratadine Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Loratadine Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The loratadine industry is fragmented in nature characterized by the presence of several pharmaceutical companies. The key market players are focused on developing improved treatments, such as longer-acting formulations and combination therapies to develop and launch new products in the market. These players are constantly engaged in growth strategies such as partnerships and collaborations, and new product launches to enhance their product portfolio.
Prominent players operating in the loratadine industry include:
The loratadine market was valued at USD 140.1 million in 2023 and is anticipated to grow at 2.8% CAGR between 2024
North America loratadine market is anticipated to reach USD 62 million by 2032, attributed to the high prevalence of allergies in the region and the well-established healthcare infrastructure and high awareness about allergy management.
The tablets segment in the loratadine industry accounted for USD 63.5 million in 2023, due to their convenience, ease of administration, and familiarity.
Bayer AG, Cadila Pharmaceuticals Limited, Cipla Ltd., Lannett Company, Inc., Merck KGaA, Morepen Laboratories Ltd, Perrigo Company plc, Pfizer Inc, Sun Pharmaceutical Industries Limited and Viatris Inc.